Dublin, March 06, 2018 -- The "United States Biopsy Market, Volume & Forecast by Segments and Companies" report has been added to ResearchAndMarkets.com's offering
United States Biopsy Market will cross US$ 17 Billion by the year 2024 owing to the rising prevalence of cancer in the region
According to the World Health Organization, cancer cases are expected to surge 57% worldwide in the next 20 years. Biopsies are most often done to look for cancer; a biopsy is a sample of tissue taken from the body in order to examine it more closely. Further, growing patient awareness and the advancement in the biopsy techniques are also expected to fuel future growth of biopsy market in United States.
The World Cancer Report, produced by the WHO's specialized cancer agency and released on World Cancer Day, predicts new cancer cases will rise from an estimated 14 million annually in 2012 to 22 million within two decades. Over the same period, cancer deaths are predicted to rise from 8.2 million a year to 13 million.
On segment basis, Breast cancer biopsies accounts for the highest share in the United States Biopsy Market for the year 2017. While, in terms of Volume, Breast cancer biopsy has second highest share. Further, the report also covers the market aspects of Liver, Lung and Thyroid cancer biopsies. The Unites States Biopsy Market and Volume will experience a major growth during the forecast period owing to the increasing number of biopsy procedures and rising demand for minimally invasive procedures
All the 8 companies studied in the report have been studied from 4 points:
- Overview
- Business Strategy
- Merger & Acquisition
- Financial Insight
Segments Covered in the Report:
- Breast Cancer Biopsy
- Prostate Cancer Biopsy
- Lung Cancer Biopsy
- Liver Cancer Biopsy
- Thyroid Cancer Biopsy
Key Topics Covered:
1. Executive Summary
2. United States Biopsy Market & Volume (2008 - 2024)
3. Share Analysis - United States Biopsy (2008 - 2024)
4. Segments Analysis - United States Biopsy Market (2008 - 2024)
5. Growth Drivers
6. Challenges
7. Company Analysis
- B. Braun Melsungen AG
- Becton, Dickinson and Company
- C. R. Bard, Inc.
- Cardinal Health, Inc.
- FUJIFILM Holdings Corporation
- Hologic, Inc
- Medtronic plc.
- Olympus Corporation
For more information about this report visit https://www.researchandmarkets.com/research/rxddrz/united_states?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Medical Devices


Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
DeepSeek to Raise AI API Prices as Demand for New Models Surges
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 



